Innate Defense Mechanism Against Virus Infection Within the Cardiac Myocyte Requiring gp130-STAT3 Signaling

Background— Little is known about innate immune mechanisms within the cardiac myocyte that determine susceptibility to enterovirus infection, an important cause of myocarditis and subsequent heart failure. Although interferon (IFN) generally plays a key role in innate immunity, ablation of IFN receptors has little or no effect on acute coxsackievirus B3 infection in the heart. Interestingly, gp130-cytokine–mediated stimulation of neonatal ventricular myocytes has a cytoprotective effect against virus infection in culture that can be inhibited by suppressors of cytokine signaling (SOCS)-3, a physiological inhibitor of gp130 signaling that does not affect IFN signaling. Therefore, we hypothesized that inhibition of gp130 signaling by SOCS3 would change cardiac myocyte susceptibility to virus infection without affecting IFN signaling. Methods and Results— We generated cardiac-specific SOCS3 transgenic mice. Despite an intact IFN-mediated antiviral response in adult transgenic myocytes, there was a marked increase in susceptibility to viral infection in the SOCS3 transgenic mouse hearts. This indicated the presence of IFN-independent innate defense mechanisms within the cardiac myocyte. Subsequently, we demonstrated that cardiac-specific gp130-knockout mice also had increased susceptibility to viral infection. Furthermore, we demonstrated that the gp130-mediated increase in survival of infected myocytes occurred through a signal transducers and activators of transcription-3–dependent mechanism that did not affect viral replication. This was accompanied by a persistent expression of full-length dystrophin after coxsackievirus B3 infection. In addition, we found that both SOCS3 transgenic and gp130-deficient mice had a decrease in α-sarcoglycan. Conclusions— SOCS3-mediated regulation of gp130 signaling can affect susceptibility to viral infection in the heart. Increased cardiac cell survival through gp130–signal transducers and activators of transcription-3 signaling appears to play an important role in preserving nondividing cardiac myocytes until specific immune responses begin to clear the virus.

[1]  E. Jeon,et al.  Long-term cardiac gene expression using a coxsackieviral vector. , 2005, Journal of molecular and cellular cardiology.

[2]  E. Fish,et al.  Protective Role for Interferon-&bgr; in Coxsackievirus B3 Infection , 2004, Circulation.

[3]  A. Dörner,et al.  Alternatively Spliced Soluble Coxsackie-adenovirus Receptors Inhibit Coxsackievirus Infection* , 2004, Journal of Biological Chemistry.

[4]  Masato Kubo,et al.  Suppressors of cytokine signaling and immunity , 2003, Nature Immunology.

[5]  G. Thiene,et al.  Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. , 2003, Cardiovascular research.

[6]  Donald Metcalf,et al.  SOCS3 negatively regulates IL-6 signaling in vivo , 2003, Nature Immunology.

[7]  Roland Lang,et al.  SOCS3 regulates the plasticity of gp130 signaling , 2003, Nature Immunology.

[8]  M. Weitzman,et al.  The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. , 2003, The Journal of clinical investigation.

[9]  J. Cross,et al.  SOCS3: an essential regulator of LIF receptor signaling in trophoblast giant cell differentiation , 2003, The EMBO journal.

[10]  Gregor Eichele,et al.  Human chromosome 21 gene expression atlas in the mouse , 2002, Nature.

[11]  C. Badorff,et al.  Dystrophin deficiency markedly increases enterovirus-induced cardiomyopathy: A genetic predisposition to viral heart disease , 2002, Nature Medicine.

[12]  Massimo Gadina,et al.  Cytokine Signaling in 2002 New Surprises in the Jak/Stat Pathway , 2002, Cell.

[13]  N. Sarvetnick,et al.  Target cell defense prevents the development of diabetes after viral infection , 2002, Nature Immunology.

[14]  G. Dorn,et al.  Cytoplasmic signaling pathways that regulate cardiac hypertrophy. , 2001, Annual review of physiology.

[15]  K. Klingel,et al.  Cardioselective Infection With Coxsackievirus B3 Requires Intact Type I Interferon Signaling: Implications for Mortality and Early Viral Replication , 2001, Circulation.

[16]  Y. Fujio,et al.  Glycoprotein 130 Regulates Cardiac Myocyte Survival in Doxorubicin-Induced Apoptosis Through Phosphatidylinositol 3-Kinase/Akt Phosphorylation and Bcl-xL/Caspase-3 Interaction , 2001, Circulation.

[17]  A Sasaki,et al.  Negative regulation of cytokine signaling pathways. , 2000, Annual review of immunology.

[18]  H. Pendeville,et al.  SOCS3 Is Essential in the Regulation of Fetal Liver Erythropoiesis , 1999, Cell.

[19]  A. Yoshimura,et al.  SOCS1 Deficiency Causes a Lymphocyte-Dependent Perinatal Lethality , 1999, Cell.

[20]  Paul J Hertzog,et al.  SOCS1 Is a Critical Inhibitor of Interferon γ Signaling and Prevents the Potentially Fatal Neonatal Actions of this Cytokine , 1999, Cell.

[21]  J. Ross,et al.  Loss of a gp130 Cardiac Muscle Cell Survival Pathway Is a Critical Event in the Onset of Heart Failure during Biomechanical Stress , 1999, Cell.

[22]  A. Yoshimura,et al.  The JAK‐binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop , 1999, The EMBO journal.

[23]  M. Martone,et al.  Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy , 1999, Nature Medicine.

[24]  K. Shuai,et al.  The Suppressor of Cytokine Signaling (SOCS) 1 and SOCS3 but Not SOCS2 Proteins Inhibit Interferon-mediated Antiviral and Antiproliferative Activities* , 1998, The Journal of Biological Chemistry.

[25]  K. Chien,et al.  Ventricular muscle-restricted targeting of the RXRalpha gene reveals a non-cell-autonomous requirement in cardiac chamber morphogenesis. , 1998, Development.

[26]  W. Leonard,et al.  Jaks and STATs: biological implications. , 1998, Annual review of immunology.

[27]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[28]  S. Akira,et al.  Structure and function of a new STAT-induced STAT inhibitor , 1997, Nature.

[29]  Takaho A. Endo,et al.  A new protein containing an SH2 domain that inhibits JAK kinases , 1997, Nature.

[30]  Warren S. Alexander,et al.  A family of cytokine-inducible inhibitors of signalling , 1997, Nature.

[31]  K. Chien,et al.  Cardiotrophin 1 (CT-1) Inhibition of Cardiac Myocyte Apoptosis via a Mitogen-activated Protein Kinase-dependent Pathway , 1997, The Journal of Biological Chemistry.

[32]  W. Mckenna,et al.  Coxsackie B viruses and human heart disease. , 1997, Current topics in microbiology and immunology.

[33]  R. Wessely,et al.  A mutation in the puff region of VP2 attenuates the myocarditic phenotype of an infectious cDNA of the Woodruff variant of coxsackievirus B3 , 1996, Journal of virology.

[34]  J. Ross,et al.  Transthoracic echocardiography in models of cardiac disease in the mouse. , 1996, Circulation.

[35]  J. Whitton,et al.  The role of CD8+ T lymphocytes in coxsackievirus B3-induced myocarditis , 1995, Journal of virology.

[36]  J. Ihle.  Cytokine receptor signalling , 1995, Nature.